Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Capecitabine in combination with Cisplatin and Trastuzumab in patients with Esophagogastric Adenocarcinoma.

Statements

Source and description

Herceptin (trastuzumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin for the treatment of adult patients with HER2 positive metastatic adenocracinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. The production information for trastuzumab in this indication further specifies that trastuzumab should only be used in patients with metastatic gastric cancer whose tumors have HER2 overexpressed as defined by IHC 2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result, as measured by an accurate and validated assay.